Summit Notebook

Exclusive outtakes from industry leaders

from Sakthi Prasad:

Real Estate – To invest or not

Abhijit Mukherjee of Dr Reddy'sEveryone of us has our own ideas about a dream home and usually wonder if it makes a good investment or not. 

But for Abhijit Mukherjee, president of the pharma firm Dr. Reddy’s, the choice is very clear -- He is not a big fan of real estate investment. 

While speaking to Reuters journalists at the India Investment Summit in Bangalore, Mukherjee cited the American example of a recent real estate crash and wondered whether India, too, is headed in the same direction. He said buying a house and holding it for value appreciation over a number of years is not a good idea.

Notwithstanding his skepticism, he said he is thinking of changing his apartment. But he was quick to add that it is not a very exciting investment.

Health reform…big in Europe too

Photo

U.S. healthcare reform is top of everybody’s agenda right now — but Barack Obama isn’t the only government leader chasing a new deal.

“If you are talking healthcare reform, it’s our daily life in Europe,” Novo Nordisk CEO Lars Sorensen told the Reuters Health Summit in New York.

Beckman hopes reform fees go up in smoke

Photo

Have healthcare companies sunk as far as controversial tobacco companies in the public eye? One medical equipment maker thinks so.

Makers of medical tests, implants and other devices face anywhere from $2 billion-a-year in industry-wide taxes in the House of Representatives’ health reform bill passed on Saturday to $4 billion-a-year under a Senate version.
The Senate measure’s tax is not deductible and would be applied much like the tobacco settlement from cigarette makers years ago, said Beckman Coulter CEO Scott Garrett.

Live blog at Reuters Health Summit

Photo

A dozen Reuters reporters are covering the annual Reuters Health Summit in New York, featuring speakers from the world’s leading healthcare companies, including Pfizer, GlaxoSmithKline, Merck, Novartis, AstraZeneca, Novo Nordisk and Eli Lilly, plus top insurers and the commissioner of the Food and Drug Administration. Follow the action as it happens:

  •